[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity",
    "summary": "Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a buying opportunity for BMY stock.",
    "url": "https://finnhub.io/api/news?id=b063f6956c071072a86cdf94f4bb126de8769d4951e60add229b470c28c18c8d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754348009,
      "headline": "Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity",
      "id": 136204755,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a buying opportunity for BMY stock.",
      "url": "https://finnhub.io/api/news?id=b063f6956c071072a86cdf94f4bb126de8769d4951e60add229b470c28c18c8d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "summary": "PRINCETON, N.J., August 04, 2025--Bristol Myers Squibb’s Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
    "url": "https://finnhub.io/api/news?id=6b91e065766745534b36dfd3a8c55a3f4ee533349eda6c2390b980d65b94ba6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338560,
      "headline": "Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
      "id": 136205940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., August 04, 2025--Bristol Myers Squibb’s Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)",
      "url": "https://finnhub.io/api/news?id=6b91e065766745534b36dfd3a8c55a3f4ee533349eda6c2390b980d65b94ba6b"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
    "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
    "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754327543,
      "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
      "id": 136202830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/505129430/image_505129430.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
      "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=17dee284df19773693af7bc1438d615e0dff471e4692f7e6310095c4629bfad1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754325660,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 136221837,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=17dee284df19773693af7bc1438d615e0dff471e4692f7e6310095c4629bfad1"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754322480,
      "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136200228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?",
    "summary": "JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.",
    "url": "https://finnhub.io/api/news?id=bd652f35b7613020e47289169149141281db27be04e3b917412a54cdce6f0f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754311860,
      "headline": "J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?",
      "id": 136200252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.",
      "url": "https://finnhub.io/api/news?id=bd652f35b7613020e47289169149141281db27be04e3b917412a54cdce6f0f38"
    }
  },
  {
    "ts": null,
    "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
    "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
    "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754310600,
      "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
      "id": 136197991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
      "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Rises as Drugmaker Beats Earnings Expectations.",
    "summary": "BioNTech  stock was rising after the drugmaker reported better-than-expected results early Monday.  The company’s second-quarter loss came in at 1.60 euros per share on revenue of €261 million ($302.1 million), beating analysts’ expectations of a loss per share of €2.28 on revenue of €151 million, according to FactSet.  Revenue doubled from €129 million a year ago, driven by its Covid-19 collaboration with  Pfizer  the drugmaker said.",
    "url": "https://finnhub.io/api/news?id=43c90363f68f283e8abf53f1e299622eaf5cd70251c60ead670a0f1fb8579aed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754308740,
      "headline": "BioNTech Stock Rises as Drugmaker Beats Earnings Expectations.",
      "id": 136198069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech  stock was rising after the drugmaker reported better-than-expected results early Monday.  The company’s second-quarter loss came in at 1.60 euros per share on revenue of €261 million ($302.1 million), beating analysts’ expectations of a loss per share of €2.28 on revenue of €151 million, according to FactSet.  Revenue doubled from €129 million a year ago, driven by its Covid-19 collaboration with  Pfizer  the drugmaker said.",
      "url": "https://finnhub.io/api/news?id=43c90363f68f283e8abf53f1e299622eaf5cd70251c60ead670a0f1fb8579aed"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update",
    "summary": "Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic tran",
    "url": "https://finnhub.io/api/news?id=79667ca0a5b1031b43bc0a4b0ef5f7d0f2b75ee3cf9c461e9403de1595245b10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754304300,
      "headline": "BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update",
      "id": 136198124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic tran",
      "url": "https://finnhub.io/api/news?id=79667ca0a5b1031b43bc0a4b0ef5f7d0f2b75ee3cf9c461e9403de1595245b10"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.",
    "summary": "BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.",
    "url": "https://finnhub.io/api/news?id=5afebd543a4915bfef689d0602fb134fbb8a63b1de5d4a6d183ba14f6c91204a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754302440,
      "headline": "BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.",
      "id": 136221838,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.",
      "url": "https://finnhub.io/api/news?id=5afebd543a4915bfef689d0602fb134fbb8a63b1de5d4a6d183ba14f6c91204a"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech SE 2Q Loss Narrows as Revenue Gains Amid Collaboration",
    "summary": "BioNTech SE 2Q Loss Narrows as Revenue Gains Amid Collaboration",
    "url": "https://finnhub.io/api/news?id=644c2741af30e7f8f20631f7e5d813a59e869c0bb0f63606b257aae9af9d3176",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754291460,
      "headline": "BioNTech SE 2Q Loss Narrows as Revenue Gains Amid Collaboration",
      "id": 136221839,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "BioNTech SE 2Q Loss Narrows as Revenue Gains Amid Collaboration",
      "url": "https://finnhub.io/api/news?id=644c2741af30e7f8f20631f7e5d813a59e869c0bb0f63606b257aae9af9d3176"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Buy The Weakness",
    "summary": "Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.",
    "url": "https://finnhub.io/api/news?id=decc74dbfac459c36a00283c70c186212b9894de48c32d82824aaf871d21fdf8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754287413,
      "headline": "Bristol-Myers Squibb: Buy The Weakness",
      "id": 136196937,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.",
      "url": "https://finnhub.io/api/news?id=decc74dbfac459c36a00283c70c186212b9894de48c32d82824aaf871d21fdf8"
    }
  }
]